SCHEMBL13197812

SCHEMBL13197812

CCCCn1cc(NC(=O)Nc2ccc(Cl)cc2C)nc1C(=O)NCCCN1CCOCC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
KLK7 P49862 1/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.45
MAPK1 P28482 1/20 0.44
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
TYRO3 Q06418 1/20 0.43
MERTK Q12866 1/20 0.43
GAS6 Q14393 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
EPHX2 P34913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2571802 0.89 KMT2A (0.47) KMT2AKLK7LMNASMN1; SMN2L3MBTL1
SCHEMBL13197805 0.83 MAPT (0.39) LMNASMN1; SMN2MAPT
SCHEMBL13197811 0.83 EPHX2 (0.38) SMN1; SMN2L3MBTL1ALDH1A1MAPTEPHX2
SCHEMBL13197808 0.82 SLC6A3 (0.37) LMNASMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL1595904 0.82 MAPT (0.42) KMT2ALMNASMN1; SMN2MAPK1ALDH1A1
SCHEMBL13197915 0.81 KMT2A (0.43) KMT2ALMNAMAPK1ALDH1A1KDM4E
SCHEMBL13197964 0.78 EPHX2 (0.59) LMNASMN1; SMN2MAPK1MAPTEPHX2
SCHEMBL13197927 0.77 LMNA (0.46) KMT2ALMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL13197783 0.76 SLC6A3 (0.39) KMT2ASMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL13197790 0.76 SLC6A3 (0.38) LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds IRF3, EIF2AK2, ZC3HAV1 KMT2A 1870/4885KLK7 4438/4885LMNA 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.